高级检索

还原响应型纳米粒通过双重机制逆转非小细胞肺癌多药耐药性的研究

Redox-responsive nanoparticles reversing non-small cell lung cancer multidrug resistance via dual mechanisms

  • 摘要: 设计一种还原响应型透明质酸-维生素E聚乙二醇琥珀酸酯载紫杉醇纳米粒(HA-SS-TPGS@PTX),探讨其在体外克服非小细胞肺癌(NSCLC)多药耐药性(MDR)的机制。采用乳化超声法制备了HA-SS-TPGS@PTX纳米粒,并利用流式细胞术和激光共聚焦显微镜等技术,研究其对耐PTX肺癌细胞(A549/T)的凋亡诱导、线粒体功能影响及P-糖蛋白(P-gp)表达的调控作用。实验结果显示,HA-SS-TPGS@PTX纳米粒在体外显著抑制A549/T细胞的增殖,IC50为1.35 μg/mL。该纳米粒通过CD44受体介导内吞进入细胞,细胞内高浓度谷胱甘肽(GSH)触发PTX和TPGS的释放,进而诱导线粒体膜电位下降,导致细胞凋亡。同时,HA-SS-TPGS@PTX还抑制了P-gp的表达及ATP的消耗,阻断了药物的外排。HA-SS-TPGS@PTX的设计为克服NSCLC多药耐药性提供了新策略。

     

    Abstract: A redox-responsive hyaluronic acid-vitamin E polyethylene glycol succinate nanoparticle loaded with paclitaxel (HA-SS-TPGS@PTX) was designed to investigate its mechanism for overcoming multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) in vitro. HA-SS-TPGS@PTX nanoparticles were prepared using an emulsion-ultrasonication method. Techniques such as flow cytometry and confocal laser scanning microscopy (CLSM) were employed to study their effects on apoptosis induction, mitochondrial function, and the regulation of P-glycoprotein (P-gp) expression in PTX-resistant lung cancer cells (A549/T). Results showed that HA-SS-TPGS@PTX nanoparticles significantly inhibited the proliferation of A549/T cells in vitro, with an IC50 of 1.35 μg/mL. The nanoparticles entered the cells via CD44 receptor-mediated endocytosis. The high intracellular concentration of glutathione (GSH) triggered the release of PTX and TPGS, which subsequently induced a decrease in mitochondrial membrane potential, leading to apoptosis. Meanwhile, HA-SS-TPGS@PTX also inhibited P-gp expression and ATP consumption, thereby blocking drug efflux. The design of HA-SS-TPGS@PTX provides a new strategy for overcoming MDR in NSCLC.

     

/

返回文章
返回